“Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients With Moderate-To-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine 4, no. 6 (October 27, 2020): s100. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/1077.